Samyang Biopharmaceuticals Corp. acquires approval for ‘Lenalid Tab’, the First Lenalidomide in Tablet Form.

- Approval for 7 doses of multiple myeloma ‘Lenalid Tab(Ingredient: Lenalidomide)’ - The first tablet formulation is about 1/3 the size of the original capsule and expects to eliminate disadvantages of capsules by improving patient compliance. - 7 different doses, diversified treatment options are expected to launch after the patent expiration (October 27) Samyang Biopharmaceuticals Corporation has developed, for the first time, the tablet (pill) form of Lenalidomide, a therapeutic agent for multiple myeloma, and acquired market approval. Samyang revealed on 17th that the approval consists of a total of 7 doses: 25, 20, 15, 10, 7.5, 5, and 2.5mg of ‘Lenalid® Tab’ (Ingredient: Lenalidomide) for multiple myeloma from the Ministry of Food and Drug Safety on August 14th. Samyang Biopharmaceuticals Corp. ‘s Lenalid Tab is a generic formulation of Celgene’s ‘Revlimid Capsule’. Compared to the size of the original capsule, the size of Samyang’s newly developed tablet is reduced to nearly 1/3rd (25mg) of the originator, making it more convenient for patient compliance.. The frequent complaints by elderly patients with regard to the capsule which were medicine getting stuck in the mouth, throat, or esophagus have been prevented with the tablet forms. The additional doses are also great news as Samyang plans to release 20, 7.5, and 2.5mg doses in addition to the existing 4 doses (25, 15, 10 and 5mg) in order to diversify treatment options for patients. An associate of Samyang Biopharmaceuticals Corp. explained, “We are in the process of insurance price negotiation and expect to launch the product after the patent expiration (October 27th). The administration of the drug is expected to be a lot easier thanks to the new formulation developed by Samyang, and patients will be able to benefit from a greater range of doses to take the medication from according to their needs.” Meanwhile, Samyang Biopharmaceuticals Corp. launched ‘Protezomib® Inj’ 2.5mg injection, a generic formulation for the ‘Velcade (Ingredient: Bortezomib Trimer), which is the first-line treatment of multiple myeloma on August 1st. The price of Protezomib Inj. 2.5mg has been set at the lowest among other domestically launched drugs, and Samyang’s Protezomib Injection is expected to contribute in reducing the financial burden on patients. Samyang Group has designated its biopharmaceutical business as its future growth engine and is focusing on maximizing Samyang Biopharmaceuticals Corp. ‘s potential to the fullest. Samyang Group founded the Biopharmaceuticals Research Center in 1992 and established Samyang Biopharmaceuticals Corporation in 2011. Samyang Biopharmaceuticals Corp. is promoting global market entry with R&D in Medical Device’s absorbable materials and Oncology products with its proprietary Drug Delivery Systems.

The release as fetched from its publisher. samyang.com ↗